| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4171 | Piperazinomycin | Antifungal antibiotic, showing inhibitory activity against fungi and yeasts, especially against Trichophyton |
|
| DCC4172 | Piperidol B2 | Novel potent in vitro and in vivo antifungal agent against azole-resistant Candida albicans |
|
| DCC4173 | Piperneolignan A | Natural nitric oxide (NO) production inhibitor |
|
| DCC4174 | Piroxicam-ß-cyclodextrin | NSAID with better gastrointestinal (GI) tolerability |
|
| DCC4175 | Pitofenone | Inhibitor of the acetylcholinesterase activity from bovine erythrocytes and electric eel |
|
| DCC4176 | Pixantrone | Inhibitor of topoisomerase II, intercalating into DNA and inducing topoisomerase II-mediated DNA strand crosslinks, resulting in inhibition of DNA replication and tumor cell cytotoxicity |
|
| DCC4177 | Pk5196 | Potent ligand to target the Y220C pocket, stabilizing Y220C |
|
| DCC4178 | Pkc-iota-in-19 | Novel Protein Kinase C-iota (PKC-ι) Inhibitor, Binding Post-kinase Domain Residues |
|
| DCC4179 | Pkcθ-in-41 | Novel selective inhibitor of protein kinase Cθ (PKCθ) |
|
| DCC4180 | Pkm2-in-8 | Novel highly potent and selective PKM2 inhibitor, blocking PKM2 mitochondrial translocation under nutritional stress and inhibits tumor growth in vivo |
|
| DCC4181 | Pks21272 | Novel potent and specific β5i inhibitor |
|
| DCC4182 | Pkumdl-ltq-301 | Potent inhibitor of HipA toxin, inhibiting E. coli persistence |
|
| DCC4183 | Pladienolide B | mRNA splicing inhibitor |
|
| DCC4184 | Plafibride | Antilipidemic and antiplatelet agent |
|
| DCC4185 | Plap Inhibitor 16 | Novel Potent and Specific Inhibitor of Placental Alkaline Phosphatase (PLAP; IC 50 = 32 nM), Targeting Tumor of the Female Reproductive Tract |
|
| DCC4186 | Plasiatine | Novel Potent Activator of the Nonreceptor Protein Tyrosine Phosphatase Shp2 |
|
| DCC4187 | Plaunotol | Gastroprotective agent, increasing the prostaglandin production in the gastric mucosa and accelerates ulcer healing |
|
| DCC4188 | Plazomicin | Broad spectrum aminoglycoside antibiotic typically used for moderate-to-severe urinary tract infections or pyelonephritis |
|
| DCC4189 | Plc Inhibitor 3017 | Novel inhibitor of phospholipase C (PLC) isozyme |
|
| DCC4190 | pl-dhn | Novel enhancer of Reactive Oxygen Species (ROS), depleting glutathione levels in analogy to piperlongumine but with reduced cell death |
|
| DCC4191 | Plectranthoic Acid | Novel activator of AMPK, inducing apoptotic death in prostate cancer cells |
|
| DCC4192 | Plhspt | Plk1 PBD-specific phosphopeptide inhibitor, effectively inhibiting mitotic progression and cell proliferation |
|
| DCC4193 | Plk1 Pbd-in-143 | Novel Inhibitor of the Polo-Box Domain of Polo-like Kinase 1 (Plk1 PBD) |
|
| DCC4194 | Plk1-in-7k | Novel polo-like kinase 1 (PLK1) inhibitor |
|
| DCC4195 | Plx647(ome) | Slightly less potent inhibitor of FMS than PLX647 but has better aqueous solubility |
|
| DCC4196 | Pm00104 | Potent anticancer tetrahydroisoquinoline alkaloid, being able to form a covalent bond with the amino group of a guanine in selected triplets of DNA duplexes and eventually give rise to double-strand breaks |
|
| DCC4197 | Pmed-1 | Novel inhibitor of β-catenin signaling, significantly reduced β-catenin activity in hepatoblastoma and several HCC cells |
|
| DCC4198 | Pmmb-317 | Novel potent irriversible dual inhibitor of tubulin and epidermal growth factor receptor (EGFR), inducing the apoptosis of A549 cells in a dose- and time-dependent manner, along with decrease in mitochondrial membrane potential (MMP), production of ROS an |
|
| DCC4199 | Pmpmease-in L-23 | Novel inhibitor of prenylated methylated protein methyl esterase (PMPMEase), a key enzyme in the reversible methylation/demethylation step in the protein prenylation pathway |
|
| DCC4200 | Pmpmease-in L-28 | Novel inhibitor of prenylated methylated protein methyl esterase (PMPMEase), a key enzyme in the reversible methylation/demethylation step in the protein prenylation pathway |
|
